Search results
Added:
2 weeks ago
EuroPCR 2026 – Dr Brian Bergmark (Brigham and Women's Hospital, Boston, MA, US) joins us to discuss findings from the VESALIUS-CV trial, examining the effect of evolocumab in patients who have undergone coronary stenting but have no prior myocardial infarction or stroke.VESALIUS-CV is a double-blind, randomised, placebo-controlled, multicentre phase 3 trial enrolling 12,301 high-cardiovascular…
View more
Added:
11 months ago
Source:
Radcliffe Cardiology
AUTHOR: Greg GuilloryThe selection of drug-eluting stents (DES) for percutaneous coronary intervention (PCI) involves balancing efficacy against safety. The SORT OUT XI randomised trial aimed to compare a newer-generation biolimus-eluting stent with a contemporary dual-therapy sirolimus-eluting stent in a real-world patient population, providing crucial head-to-head evidence.¹SORT OUT XI was a…
View more
Stenting Strategies in Left Main Bifurcation
Added:
3 months ago
Systematic Review
Added:
7 months ago
TCT 2025 - Short-term anticoagulation reduced adverse events following left atrial appendage closure (LAAC) compared to dual antiplatelet therapy (DAPT).Dr Josep Rodés-Cabau (Quebec Heart and Lung Institute, Quebec, CA) joins us at TCT 2025 to discuss findings from ANDES trial (NCT03568890) investigating the safety and efficacy of short-term anticoagulation versus DAPT for preventing device…
View more
Added:
9 months ago
Presented at the European Society of Cardiology (ESC) Congress 2025, Prof Carolyn Lam (Singapore, UK), Prof Davide Capodanno (Catania, IT), Dr Sneha Shah Jain (Stanford, US) and Prof Jeffrey Weitz (Hamilton, CA) examine the prevalence and challenges of stroke prevention in atrial fibrillation (AF) and after acute coronary syndrome (ACS). The faculty review current treatment guidelines, explore…
View more
Stent Underexpansion and Aorto-ostial Lesions Management
Added:
1 year ago
Review Article
Added:
9 months ago
Hear from Prof Carolyn Lam and Prof Jeffrey Weitz as they share key take-home messages from ESC 2025.Filmed onsite, this peer-to-peer discussion distils the latest updates in thrombosis management for acute coronary syndrome (ACS), secondary stroke prevention (SSP) and atrial fibrillation (AF).Register for the upcoming Q&A webinar, taking place on 6 October (14:00 EDT / 20:00 CEST), to put your…
View more
Start date:
Oct 06, 2025
Following the ESC 2025 symposium 'Revolutionising Thrombosis Treatment in ACS, SSP and AF – Bridging the Gaps With Next Generation Anticoagulation Strategies', this live Q&A webinar offers an exclusive chance to continue the conversation.Join Prof Carolyn Lam (Singapore, UK), Prof Jeffrey Weitz (Hamilton, CA) and Dr Sneha Shah Jain (Stanford, US) as they address your questions on stroke…
View more
Added:
1 year ago
ACC 2025 - Primary findings from EARLY-TAVR show the benefit of early TAVR intervention was consistent across biomarker subgroups.Dr Brian Lindman (Vanderbilt University Medical Center, Nashville, US) joins us onsite at ACC 2025 to discuss findings from the primary biomarker analysis from the EARLY TAVR trial (NCT03042104; Edwards Lifesciences). The analysis investigated cardiac biomarkers in…
View more
Added:
11 months ago
New York Valves 2025 -Dr Santiago Garcia (The Christ Hospital, Cincinnati, OH, US) joins us to discuss outcomes from an observational study investigating early outcomes of the Navitor self-expandable transcatheter valve with intra-annular leaflet position. Approximately 3,000 patients with severe, symptomatic aortic stenosis, high surgical risk and tricuspid anatomy were enrolled in the study and…
View more